vs
PRECISION BIOSCIENCES INC（DTIL）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
PRECISION BIOSCIENCES INC的季度营收约是REGENXBIO Inc.的1.1倍（$34.2M vs $30.3M），PRECISION BIOSCIENCES INC净利率更高（58.9% vs -221.3%，领先280.2%），PRECISION BIOSCIENCES INC同比增速更快（5261.1% vs 43.0%），PRECISION BIOSCIENCES INC自由现金流更多（$-11.3M vs $-52.8M），过去两年PRECISION BIOSCIENCES INC的营收复合增速更高（39.5% vs 39.4%）
精准生物科学公司是一家上市的美国临床阶段基因编辑企业，总部位于北卡罗来纳州达勒姆，成立于2006年。该公司依托自主研发的ARCUS基因组编辑平台，专注于开发体内和体外两类基因编辑疗法。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
DTIL vs RGNX — 直观对比
营收规模更大
DTIL
是对方的1.1倍
$30.3M
营收增速更快
DTIL
高出5218.1%
43.0%
净利率更高
DTIL
高出280.2%
-221.3%
自由现金流更多
DTIL
多$41.5M
$-52.8M
两年增速更快
DTIL
近两年复合增速
39.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $34.2M | $30.3M |
| 净利润 | $20.1M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 36.6% | -190.0% |
| 净利率 | 58.9% | -221.3% |
| 营收同比 | 5261.1% | 43.0% |
| 净利润同比 | 213.5% | -31.2% |
| 每股收益（稀释后） | $2.62 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DTILRGNX
| Q4 25 | $34.2M | $30.3M | ||
| Q3 25 | $13.0K | $29.7M | ||
| Q2 25 | $18.0K | $21.4M | ||
| Q1 25 | $29.0K | $89.0M | ||
| Q4 24 | $638.0K | $21.2M | ||
| Q3 24 | $576.0K | $24.2M | ||
| Q2 24 | $49.9M | $22.3M | ||
| Q1 24 | $17.6M | $15.6M |
净利润DTILRGNX
| Q4 25 | $20.1M | $-67.1M | ||
| Q3 25 | $-21.8M | $-61.9M | ||
| Q2 25 | $-23.5M | $-70.9M | ||
| Q1 25 | $-20.6M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $-16.4M | $-59.6M | ||
| Q2 24 | $32.7M | $-53.0M | ||
| Q1 24 | $8.6M | $-63.3M |
毛利率DTILRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率DTILRGNX
| Q4 25 | 36.6% | -190.0% | ||
| Q3 25 | -158976.9% | -176.3% | ||
| Q2 25 | -121538.9% | -296.3% | ||
| Q1 25 | -76248.3% | 13.6% | ||
| Q4 24 | — | -242.1% | ||
| Q3 24 | -3693.6% | -256.6% | ||
| Q2 24 | 48.4% | -251.3% | ||
| Q1 24 | -23.8% | -408.8% |
净利率DTILRGNX
| Q4 25 | 58.9% | -221.3% | ||
| Q3 25 | -167476.9% | -208.3% | ||
| Q2 25 | -130666.7% | -331.8% | ||
| Q1 25 | -70913.8% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | -2851.6% | -246.3% | ||
| Q2 24 | 65.6% | -237.7% | ||
| Q1 24 | 48.8% | -405.4% |
每股收益（稀释后）DTILRGNX
| Q4 25 | $2.62 | $-1.30 | ||
| Q3 25 | $-1.84 | $-1.20 | ||
| Q2 25 | $-2.13 | $-1.38 | ||
| Q1 25 | $-2.21 | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | $-2.25 | $-1.17 | ||
| Q2 24 | $4.67 | $-1.05 | ||
| Q1 24 | $1.70 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $115.6M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $92.2M | $102.7M |
| 总资产 | $154.4M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DTILRGNX
| Q4 25 | $115.6M | $230.1M | ||
| Q3 25 | $44.9M | $274.2M | ||
| Q2 25 | $62.2M | $323.3M | ||
| Q1 25 | $77.2M | $267.9M | ||
| Q4 24 | $86.3M | $234.7M | ||
| Q3 24 | $101.2M | $255.5M | ||
| Q2 24 | $123.6M | $290.4M | ||
| Q1 24 | $137.8M | $338.7M |
股东权益DTILRGNX
| Q4 25 | $92.2M | $102.7M | ||
| Q3 25 | $16.6M | $161.5M | ||
| Q2 25 | $34.1M | $213.7M | ||
| Q1 25 | $49.3M | $274.2M | ||
| Q4 24 | $56.4M | $259.7M | ||
| Q3 24 | $64.9M | $301.4M | ||
| Q2 24 | $74.7M | $348.3M | ||
| Q1 24 | $37.2M | $390.7M |
总资产DTILRGNX
| Q4 25 | $154.4M | $453.0M | ||
| Q3 25 | $93.5M | $525.2M | ||
| Q2 25 | $108.9M | $581.0M | ||
| Q1 25 | $124.4M | $490.9M | ||
| Q4 24 | $136.4M | $466.0M | ||
| Q3 24 | $153.3M | $519.1M | ||
| Q2 24 | $165.8M | $569.4M | ||
| Q1 24 | $184.7M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-11.3M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-11.3M | $-52.8M |
| 自由现金流率自由现金流/营收 | -32.9% | -174.0% |
| 资本支出强度资本支出/营收 | 0.1% | 1.7% |
| 现金转化率经营现金流/净利润 | -0.56× | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流DTILRGNX
| Q4 25 | $-11.3M | $-52.3M | ||
| Q3 25 | $-15.3M | $-56.0M | ||
| Q2 25 | $-20.3M | $-49.3M | ||
| Q1 25 | $-19.1M | $33.6M | ||
| Q4 24 | $-58.4M | $-31.6M | ||
| Q3 24 | $-5.9M | $-40.5M | ||
| Q2 24 | $-14.9M | $-45.5M | ||
| Q1 24 | $-19.0M | $-55.5M |
自由现金流DTILRGNX
| Q4 25 | $-11.3M | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | $-20.3M | $-49.7M | ||
| Q1 25 | $-19.1M | $32.6M | ||
| Q4 24 | $-58.7M | $-32.7M | ||
| Q3 24 | $-6.0M | $-40.9M | ||
| Q2 24 | $-14.9M | $-46.0M | ||
| Q1 24 | $-19.1M | $-56.0M |
自由现金流率DTILRGNX
| Q4 25 | -32.9% | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | -112627.8% | -232.8% | ||
| Q1 25 | -65917.2% | 36.6% | ||
| Q4 24 | -9199.8% | -154.2% | ||
| Q3 24 | -1033.2% | -168.9% | ||
| Q2 24 | -29.9% | -206.2% | ||
| Q1 24 | -108.4% | -358.5% |
资本支出强度DTILRGNX
| Q4 25 | 0.1% | 1.7% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 11.1% | 1.8% | ||
| Q1 25 | 220.7% | 1.2% | ||
| Q4 24 | 39.2% | 5.1% | ||
| Q3 24 | 6.8% | 1.3% | ||
| Q2 24 | 0.1% | 2.1% | ||
| Q1 24 | 0.5% | 3.6% |
现金转化率DTILRGNX
| Q4 25 | -0.56× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -0.45× | — | ||
| Q1 24 | -2.21× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DTIL
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
